TLX · Telix Pharmaceuticals Ltd
$11.75
-0.07 (-0.59%)
At close · Aug 17
Market Cap
$4.00B
Shares
338.78M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$11.82
Open$11.96
Day$11.75–11.99
52W close$6.41–12.54
Avg vol 30d120K
Short int278K · 0.1% float · 2.6d
Short vol34%
Last earningsAug 20, 2026
DataNov 2024–Aug 2026
Up next
Next earnings call
Aug 20, 2026
Scheduled
· this week
FQ3-26 quarter ends
~Sep 30, 2026
Est
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Strong Buy
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+27%
above
Price vs 50-day avg
+11%
above
RSI (14)
61
neutral
MACD trend
Positive
52-week position
88%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+13%
trailing
6-month return
+70%
trailing
YTD return
+58%
this year
Relative strength
+56%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $11 › 200d $9 — 50d above 200d
Institutional flow
Accumulating
+55% holders QoQ · +25 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.08% of float · ▼ -6.6% MoM · 2.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
62 holders — near 2-yr high, broad support
Squeeze score
51
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
58%
annualized · 1-yr
Max drawdown
−49%
past year
ATR
3.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Prior guidance
period ended
· from the Earnings Call filed Jun 30, 2025
Revenues from Illuccix and RLS
· full-year
$770M – $800M
R&D investments
· full-year
20% – 25%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+27%
Bullish
Price vs 50-day avg
+11%
Bullish
RSI (14)
61
Neutral
MACD trend
Positive
Bullish
52-week position
88%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $11 › 200d $9 — 50d above 200d
Institutional flow
Accumulating
+55% holders QoQ · +25 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.08% of float · ▼ -6.6% MoM · 2.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
62 holders — near 2-yr high, broad support
Price context
position in its 52-week range
Range low $6
Now $12 · 88%
Range high $13
vs 200-day avg +27%
vs 50-day avg +11%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TLX
this stock
Telix Pharmaceuticals Ltd
|
$4.00B | +57.8% | — | — | 0.1% |
|
ONC
BeOne Medicines Ltd.
|
$513.62B | +14.4% | +22179.2% | 789.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$128.19B | +11.6% | +46.2% | 29.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$82.72B | +4.1% | +20.8% | 19.9 | 3.3% |
|
ARGX
Argenx SE
|
$52.94B | +1.2% | — | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TLX | +2.6% | +13.0% | +70.1% | +19.5% | +57.8% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | +2.2% | +8.6% | +56.3% | +15.6% | +44.0% |
Key facts
CIK
2007191
CUSIP
87961M105
13F (30d)
58 filings
58 filers
Visit website
Investor relations